San Diego – January 3, 2019 – Cooley advised Taiwan Liposome Company on its $22.7 million initial public offering of 3,915,550 American Depository Shares – each representing two common shares. Partners Charlie Kim, Robert Phillips, James Lu and David Peinsipp led the Cooley team advising Taiwan Liposome Company.
Cantor acted as book-running manager for the offering. CLSA, HC Wainwright & Co., Janney Montgomery Scott and Laidlaw & Company UK Ltd. acted as book-runners.
Taiwan Liposome Company, whose securities now trade on the Nasdaq Global Market under the symbol “TLC,” is a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines to target areas of unmet medical need in pain management, ophthalmology and oncology.
Cooley has now represented the only two Taipei Exchange-listed companies to go public in the US to date – TLC and ASLAN Pharmaceuticals in June 2018.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 1,000+ lawyers across 13 offices in the United States, China and Europe.